Exagen (XGN): Revenue Growth Outlook Challenges Bearish Sentiment as Valuation Remains Undemanding

Exagen (XGN) remains unprofitable, but the company has managed to cut its annual losses by 4.7% over the last five years. While forecasts call for continued red ink over the next three years, revenue ...